MoriVid (hydroxychloroquine sulfate) 200 mg, 30 tablets, expected by thousands of Bulgarian patients, is now available in the pharmacies countrywide. The distributor of the medicinal product is Commercial League – Global Pharma Center.
Prof. Toni Vekov – Director of the scientific board of Tchaikapharma, prof. Rasho Rashkov – Chairman of the Bulgarian Rheumatology Society and Boryana Boteva – Chairman of the Rheumatology Patients Organisation took part in the broadcasting “Ask BNT” related to the matters of efficiency and safety of the treatment with Hydroxychloroquine (HCQ) for rheumatology-related diseases and as therapy for COVID-19.
Prof. Toni Vekov: The product is already registered in Bulgaria, we have been assured by the National Organization of prices and re-imbursement of pharmaceutical products, that the price will be discussed on Thursday (18th of June). I hope MoriVid to be available in all pharmacies as of next week.
A representative epidemiological study leaded by our research team, which included 56 countries, showed that in countries where 5 times more HCQ is used, mortality is 2 times lower.
Prof. Rasho Rashkov: I work with Hydroxychloroquine for 36 years. The Chloroquine and the Hydroxychloroquine have a good effect [if the right dosage is applied] and are safe to a significant extent. The product is efficient in cases of COVID-19 infections as well.
B. Boteva: The registration of the Hydroxychloroquine is Bulgaria is an immense achievement. Many thanks to the pharmaceutical company!
Watch the full interview here /in Bulgarian/.
(updated on 5 June, 14:30 )
In response to numerous inquiries from doctors, journalists and especially from patients suffering from autoimmune diseases, we confirm inform that Tchaikapharma High Quality Medicines Inc. has developed, produced and registered for use in Bulgaria hydroxychloroquine sulfate in one galenic form. The regulatory approval is highly anticipated and very welcomed. So far, more than 4,000 people have been forced to seek the medicine from abroad or to stop their treatment, which dramatically worsens their quality of life and compromises their further treatment.
We recall that after the stark opposition and widespred reaction of the international scientific community against the publication of May 22, 2020 with fabricated data in the otherwise authoritative medical scientific journal Lancet, yesterday, June 3, 2020, the World Health Organization resumed all clinical trials of hydroxychloroquine for treatment of COVID-19. The researchers from Harvard and authors of the Lancet article were forced to wear sackloth and ashes and retracted it against the disclosure of data fabrication. Just an hour later, a second article published in another legendary scientific forum, the New England Journal of Medicine, was retracted for the acknowledged use of inaccurate data collected in compromised ways and without probative value.
MoriVid will be available in hospitals and in all pharmacies within days.
MoriVid will be registered in 10 European countries by the end of the year.
International Press Center
Leading cardiac surgeon Prof. Vladimir Danov to the press:
“Tchaikapharma” developed a production technology for a period so short that is worthy of a record and registered in Bulgaria Hydroxychloroquine Sulfate, which is wonderful news for more than four thousand Bulgarians, suffering from autoimmune diseases.
You can read the whole interview here in Bulgarian.
Tchaikapharma High Quality Medicines AD (BSE: 7TH) intends to build a third manufacturing plant in the village of Kazichene near Sofia. This became clear from documents published in the Commercial Register in connection with the forthcoming general meeting of shareholders, scheduled for June 22, 2020.
The investment is scheduled to be completed by the end of 2022 and its workload will be almost achieved by 2026 in a favorable economic environment. The company plans to increase its production capacity with 500 million tablets annually in addition to the 450 million currently produced.
The company has two plants – one in Varna and one in Plovdiv. Both structures operate at almost maximum capacity and produce almost 160 medicinal products.
Tchaikapharma currently has long-term partnership agreements for the sale of medicines with companies from the Czech Republic, Slovakia, Germany, Kosovo and Yemen. Advanced negotiations are also underway with other EU companies. A few more long-term contracts are expected by the end of the year.
Find the full article here in Bulgarian.
Professor Toni Vekov in an interview with NOVA: Tchaikapharma R&D Team worked around the clock to develop our own dossier
Within the next ten days, Tchaikapharma will produce about 5,000 packs of MoriVir (hydroxychloroquine), and in another week, at least 20,000 packs of GraVir (chloroquine). “Every Bulgarian diagnosed with COVID-19 will have the opportunity to be treated”, said Vekov, biotechnology engineer and one of Tchaikapharma’s founders.
See the full interview here in Bulgarian.